Regenerative Medicine

nSTRIDE® APS Injection

Advanced injection therapy for knee osteoarthritis relief.

Available at these clinics:

Mississauga

Oakville

About the service

Advanced, ultrasound-guided injection therapy for knee osteoarthritis relief.

About nSTRIDE® APS

At MedCAiRE Health, we offer nSTRIDE® APS (Autologous Protein Solution), a cutting-edge, blood-derived injection designed to help reduce knee osteoarthritis pain by targeting inflammation at its biological source. Using on-site processing and real-time ultrasound guidance, nSTRIDE delivers a concentrated solution from your own blood directly into the knee joint.

What is nSTRIDE® APS?

nSTRIDE is an autologous biologic therapy that concentrates anti-inflammatory proteins and growth factors from your own blood, then injects that solution into the knee joint under ultrasound guidance for accuracy.

Your nSTRIDE APS solution may include:

  • IL-1 receptor antagonists (IL-1ra) to help block key inflammatory pathways
  • Growth factors that support joint repair
  • Anti-catabolic proteins that may help slow joint breakdown

nSTRIDE is not a steroid and not a lubricant. It is a biologically targeted option aimed at interrupting the inflammatory cascade involved in cartilage deterioration.

Why Ultrasound Guidance Matters

At MedCAiRE, nSTRIDE injections are performed under ultrasound guidance to support:

  • Precise joint-space targeting
  • Accurate delivery of the solution
  • Improved safety and reduced risk of misplacement

When helpful, X-ray imaging can also be used to confirm osteoarthritis severity and joint anatomy prior to treatment.

Benefits of nSTRIDE® APS

nSTRIDE is designed to support:

  • Long-lasting pain relief (often 6–12 months or more)
  • Improved mobility and daily function
  • A targeted approach that addresses inflammation at the molecular level
  • A single, image-guided injection (non-surgical and autologous)

✅ Who is a Good Candidate?

You may be a good fit if you:

  • Have mild to moderate knee osteoarthritis
  • Want to avoid surgery or frequent steroid injections
  • Have had limited response to treatments like PRP, corticosteroids, or hyaluronic acid
  • Want a biologic option using your own blood

Not sure if you qualify? We confirm this during your assessment and imaging review.

How to Book at MedCAiRE

Step 1: Schedule Your Assessment

  • **Book Now Button**

Step 2: Assessment + Diagnostic Ultrasound

We start with a focused knee history and exam, followed by review of any diagnostics to assess joint structure and osteoarthritis severity.

If needed, we may recommend further X-rays/ultrasound/MRI to confirm the stage and alignment factors that affect outcomes.

Step 3: In-clinic procedure (same visit)

1) Blood draw

A small blood sample is taken from your arm.

2) On-Site Processing

Your blood is processed on-site to prepare the APS solution.

3) Ultrasound-Guided Injection

The APS solution is injected precisely into the knee joint under ultrasound guidance.

Step 4: Aftercare + Follow-Up

Most clients return to light activity within 24–48 hours. A personalized rehab plan may be provided based on your goals, symptoms, and exam findings.

Results Timeline

  • Some patients report improvement within 2–4 weeks
  • Peak effects are often seen around 2–3 months
  • Many clients experience meaningful relief for up to 12 months, depending on osteoarthritis severity, activity demands, biomechanics, and overall joint health

Pricing 💳

  • nSTRIDE® APS Injection (ultrasound-guided): $1290
Book an Appointment

Frequently Asked Questions

Is the injection painful?

Most patients tolerate the procedure well. Local anesthetic may be used, and ultrasound guidance supports comfort and precision.

Will I need more than one injection?

nSTRIDE is designed as a single-injection treatment, but some patients may benefit from re-evaluation if symptoms return (often around the 12-month mark).

Is nSTRIDE covered by OHIP or insurance?

nSTRIDE is not covered by OHIP. Some extended health plans may reimburse a portion depending on your plan.

Is this backed by research?

APS has been studied for early to moderate knee OA and has shown symptom improvement with a favorable safety profile in published clinical research.